Revisor Wealth Management’s Idexx Laboratories IDXX Stock Holding History

Revisor Wealth Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-560	Closed	-$245K	–	150
2023 Q3	$245K	Sell	560 -280	-33%	-$140K	0.21%	132
2023 Q2	$422K	Sell	840 -123	-13%	-$58.9K	0.38%	62
2023 Q1	$482K	Buy	+963	New	+$461K	0.44%	52

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Revisor Wealth Management's IDXX Position: Q4 2023 in Review

Revisor Wealth Management sold out of Idexx Laboratories (IDXX) in Q4 2023, closing a stake of 560 shares — an estimated $245K sold.

Revisor Wealth Management first reported a position in IDXX in Q1 2023 and held it in 3 quarters. The position peaked at $482K in Q1 2023. 1,153 funds tracked by Wall St. Rank hold IDXX as of Q4 2023.

Revisor Wealth Management reported no remaining Idexx Laboratories position as of Q4 2023 after selling out during the quarter.
Revisor Wealth Management sold 560 Idexx Laboratories shares in Q4 2023, an estimated $245K.
Revisor Wealth Management first reported a position in Idexx Laboratories in Q1 2023 and held it in 3 quarters.
Revisor Wealth Management's Idexx Laboratories position peaked at $482K in Q1 2023.
1,153 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2023.

Based on Revisor Wealth Management's 13F filing for Q4 2023, filed 10 Jan 2024.